Q&A: Flexible Expression Technologies For Mammalian And Microbial Proteins

A rapidly growing market of new mammalian- and microbial-derived molecular formats are showing great promise and new possibilities in patient care. However, the commercial success of these products requires appropriate expression technologies and development processes that fit their unique needs. Without these tools, you may encounter issues that lead to added costs and delayed time to clinic or market. Considering these emerging challenges in today’s changing industry, it is critical to work with a flexible partner that can provide solutions as well as the guidance and process development expertise necessary to de-risk your manufacturing process.

In a recent webinar, Dr. Joachim Klein, Head of Microbial Strain Development and Cell Banking, and Dr. Rebecca Michael, Principal Group Leader of the Cell and Molecular Biology Group discussed Lonza’s options for expressing and manufacturing complex biologic drugs. These subject matter experts provided an overview of Lonza’s mammalian and microbial expression systems and processes as well as case studies demonstrating the range of capabilities across mammalian- and microbial-derived molecules. This Q&A session was held after this webinar, where Drs. Klein and Michael were able to address attendee questions about the details of the presentation and case studies.